$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

$lxrx Overview Financials Valuation SEC Filings Company Website

2020 Q4 Form 10-Q Financial Statement

#000106282220000067 Filed on October 30, 2020

Income Statement

Concept	2020 Q4	2020 Q3	2019 Q4
Revenue	$200.0K	$6.634M	$8.727M
YoY Change	-97.71%	-97.75%	-48.88%
Cost Of Revenue	$0.00	$633.0K	$800.0K
YoY Change	-100.0%	9.71%	33.33%
Gross Profit	$200.0K	$6.001M	$8.000M
YoY Change	-97.5%	-97.96%	-52.38%
Gross Profit Margin	100.0%	90.46%	91.67%
Selling, General & Admin	$6.400M	$12.00M	$14.60M
YoY Change	-56.16%	-13.67%	-12.05%
% of Gross Profit	3200.0%	199.97%	182.5%
Research & Development	$1.000M	$40.15M	$40.60M
YoY Change	-97.54%	50.59%	235.54%
% of Gross Profit	500.0%	669.01%	507.5%
Depreciation & Amortization	$300.0K	$800.0K	$1.000M
YoY Change	-70.0%	-11.11%	11.11%
% of Gross Profit	150.0%	13.33%	12.5%
Operating Expenses	$7.400M	$52.78M	$55.10M
YoY Change	-86.57%	-24.36%	92.66%
Operating Profit	-$7.200M	$86.68M	-$47.22M
YoY Change	-84.75%	-61.42%	281.8%
Interest Expense	-$200.0K	$4.118M	-$5.200M
YoY Change	-96.15%	-20.87%	0.0%
% of Operating Profit		4.75%
Other Income/Expense, Net	$900.0K	$301.0K	$1.300M
YoY Change	-30.77%	-49.83%	62.5%
Pretax Income	-$5.500M	$82.60M	-$51.10M
YoY Change	-89.24%	-62.47%	213.5%
Income Tax	$0.00	$0.00	$0.00
% Of Pretax Income		0.0%
Net Earnings	-$5.500M	$82.60M	-$51.14M
YoY Change	-89.24%	-63.46%	204.72%
Net Earnings / Revenue	-2750.0%	1245.15%	-585.97%
Basic Earnings Per Share		$0.77	-$0.48
Diluted Earnings Per Share	-$44.93K	$0.71	-$0.48
COMMON SHARES
Basic Shares Outstanding	117.5M shares	107.3M shares	106.3M shares
Diluted Shares Outstanding		117.6M shares	106.3M shares

Balance Sheet

Concept	2020 Q4	2020 Q3	2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$152.3M	$111.4M	$271.7M
YoY Change	-43.95%	-62.4%	69.71%
Cash & Equivalents	$126.3M	$52.25M	$36.11M
Short-Term Investments	$26.00M	$59.20M	$235.5M
Other Short-Term Assets	$5.049M	$9.109M	$5.320M
YoY Change	-5.09%	52.5%	99.4%
Inventory	$0.00	$0.00	$4.243M
Prepaid Expenses
Receivables	$395.0K	$1.383M	$56.53M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$157.7M	$121.9M	$337.8M
YoY Change	-53.3%	-66.46%	94.87%
LONG-TERM ASSETS
Property, Plant & Equipment	$295.0K	$11.11M	$14.05M
YoY Change	-97.9%	-23.62%	-11.46%
Goodwill	$44.54M	$44.54M	$44.54M
YoY Change	0.0%	0.0%	0.0%
Intangibles		$0.00	$19.70M
YoY Change		-100.0%	-60.69%
Long-Term Investments
YoY Change
Other Assets	$1.231M	$1.341M	$1.655M
YoY Change	-25.62%	-23.55%	480.7%
Total Long-Term Assets	$46.07M	$56.99M	$79.96M
YoY Change	-42.39%	-29.64%	-27.84%
TOTAL ASSETS
Total Short-Term Assets	$157.7M	$121.9M	$337.8M
Total Long-Term Assets	$46.07M	$56.99M	$79.96M
Total Assets	$203.8M	$178.9M	$417.7M
YoY Change	-51.21%	-59.75%	47.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.469M	$11.73M	$12.18M
YoY Change	-55.09%	-43.88%	1.05%
Accrued Expenses	$29.69M	$58.50M	$42.15M
YoY Change	-29.56%	408.18%	98.4%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$11.65M	$8.691M	$11.01M
YoY Change	5.76%	-23.01%	887.62%
Total Short-Term Liabilities	$46.81M	$78.92M	$65.34M
YoY Change	-28.37%	76.07%	77.79%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$11.63M	$234.2M
YoY Change	-100.0%	-95.03%	-3.98%
Other Long-Term Liabilities	$611.0K	$738.0K	$1.102M
YoY Change	-44.56%	-39.26%	363.03%
Total Long-Term Liabilities	$611.0K	$12.37M	$235.3M
YoY Change	-99.74%	-94.74%	-3.63%
TOTAL LIABILITIES
Total Short-Term Liabilities	$46.81M	$78.92M	$65.34M
Total Long-Term Liabilities	$611.0K	$12.37M	$235.3M
Total Liabilities	$47.42M	$91.29M	$300.6M
YoY Change	-84.23%	-67.38%	-3.2%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.400B	-$1.395B	-$1.341B
YoY Change	4.37%	8.08%	-8.84%
Common Stock	$142.0K	$117.0K	$106.0K
YoY Change	33.96%	10.38%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$4.843M	$4.843M	$3.817M
YoY Change	26.88%	26.88%	32.72%
Treasury Stock Shares	793.0K shares	793.0K shares	407.0K shares
Shareholders Equity	$156.4M	$87.64M	$117.1M
YoY Change
Total Liabilities & Shareholders Equity	$203.8M	$178.9M	$417.7M
YoY Change	-51.21%	-59.75%	47.01%

Cashflow Statement

Concept	2020 Q4	2020 Q3	2019 Q4
OPERATING ACTIVITIES
Net Income	-$5.500M	$82.60M	-$51.14M
YoY Change	-89.24%	-63.46%	204.72%
Depreciation, Depletion And Amortization	$300.0K	$800.0K	$1.000M
YoY Change	-70.0%	-11.11%	11.11%
Cash From Operating Activities	-$34.30M	-$40.30M	-$24.40M
YoY Change	40.57%	-121.13%	-9.96%
INVESTING ACTIVITIES
Capital Expenditures	-$100.0K	$0.00	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$44.10M	$215.8M	-$109.4M
YoY Change	-140.31%	-789.46%	-286.05%
Cash From Investing Activities	$44.10M	$215.8M	-$109.4M
YoY Change	-140.31%	-789.46%	-286.05%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	64.20M	-210.1M	-300.0K
YoY Change	-21500.0%	69933.33%	200.0%
NET CHANGE
Cash From Operating Activities	-34.30M	-40.30M	-24.40M
Cash From Investing Activities	44.10M	215.8M	-109.4M
Cash From Financing Activities	64.20M	-210.1M	-300.0K
Net Change In Cash	74.00M	-34.60M	-134.1M
YoY Change	-155.18%	-121.75%	-524.37%
FREE CASH FLOW
Cash From Operating Activities	-$34.30M	-$40.30M	-$24.40M
Capital Expenditures	-$100.0K	$0.00	$0.00
Free Cash Flow	-$34.20M	-$40.30M	-$24.40M
YoY Change	40.16%	-121.13%	-9.96%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001062822
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2020-09-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-30111
CY2020Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	117474808	shares
	dei	Entity Registrant Name EntityRegistrantName	Lexicon Pharmaceuticals, Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	76-0474169
	dei	Entity Address Address Line1 EntityAddressAddressLine1	8800 Technology Forest Place
	dei	Entity Address City Or Town EntityAddressCityOrTown	The Woodlands
	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	77381
	dei	City Area Code CityAreaCode	281
	dei	Local Phone Number LocalPhoneNumber	863-3000
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001
	dei	Trading Symbol TradingSymbol	LXRX
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52251000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36112000	USD
CY2020Q3	us-gaap	Short Term Investments ShortTermInvestments	59195000	USD
CY2019Q4	us-gaap	Short Term Investments ShortTermInvestments	235547000	USD
CY2020Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1383000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	56532000	USD
CY2020Q3	us-gaap	Inventory Net InventoryNet	0	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	4243000	USD
CY2020Q3	us-gaap	Other Assets Current OtherAssetsCurrent	9109000	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	5320000	USD
CY2020Q3	us-gaap	Assets Current AssetsCurrent	121938000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	337754000	USD
CY2020Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	63795000	USD
CY2019Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	61741000	USD
CY2020Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11106000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14047000	USD
CY2020Q3	us-gaap	Goodwill Goodwill	44543000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	44543000	USD
CY2020Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	19716000	USD
CY2020Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1341000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1655000	USD
CY2020Q3	us-gaap	Assets Assets	178928000	USD
CY2019Q4	us-gaap	Assets Assets	417715000	USD
CY2020Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	11734000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	12178000	USD
CY2020Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	58497000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	42151000	USD
CY2020Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	8691000	USD
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	11012000	USD
CY2020Q3	us-gaap	Liabilities Current LiabilitiesCurrent	78922000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	65341000	USD
CY2020Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	11629000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	234171000	USD
CY2020Q3	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	738000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1102000	USD
CY2020Q3	us-gaap	Liabilities Liabilities	91289000	USD
CY2019Q4	us-gaap	Liabilities Liabilities	300614000	USD
CY2020Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2019Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2019Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2019Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2020Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	225000000	shares
CY2020Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	117231000	shares
CY2019Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	106679000	shares
CY2020Q3	us-gaap	Common Stock Value CommonStockValue	117000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	106000	USD
CY2020Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1486853000	USD
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1462172000	USD
CY2020Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1394523000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1341444000	USD
CY2020Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	35000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	84000	USD
CY2020Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	793000	shares
CY2019Q3	us-gaap	Treasury Stock Shares TreasuryStockShares	407000	shares
CY2020Q3	us-gaap	Treasury Stock Value TreasuryStockValue	4843000	USD
CY2019Q4	us-gaap	Treasury Stock Value TreasuryStockValue	3817000	USD
CY2020Q3	us-gaap	Stockholders Equity StockholdersEquity	87639000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	117101000	USD
CY2020Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	178928000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	417715000	USD
CY2020Q3	lxrx	Netproductrevenue Netproductrevenue	6542000	USD
CY2019Q3	lxrx	Netproductrevenue Netproductrevenue	8351000	USD
	lxrx	Netproductrevenue Netproductrevenue	23404000	USD
	lxrx	Netproductrevenue Netproductrevenue	23763000	USD
CY2020Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	0	USD
CY2019Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	285910000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	33000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	289209000	USD
CY2020Q3	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	92000	USD
CY2019Q3	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	187000	USD
	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	359000	USD
	us-gaap	Royalty Income Nonoperating RoyaltyIncomeNonoperating	374000	USD
CY2020Q3	us-gaap	Revenues Revenues	6634000	USD
CY2019Q3	us-gaap	Revenues Revenues	294448000	USD
	us-gaap	Revenues Revenues	23796000	USD
	us-gaap	Revenues Revenues	313346000	USD
CY2020Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	633000	USD
CY2019Q3	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	577000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1929000	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2457000	USD
CY2020Q3	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	1029000	USD
CY2019Q3	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	1698000	USD
	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	5154000	USD
	lxrx	Stock Based Compensation Expense Associated With Research And Development Expense StockBasedCompensationExpenseAssociatedWithResearchAndDevelopmentExpense	5369000	USD
CY2020Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	40147000	USD
CY2019Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	26659000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	152629000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	51318000	USD
CY2020Q3	lxrx	Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense	875000	USD
CY2019Q3	lxrx	Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense	1864000	USD
	lxrx	Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense	5440000	USD
	lxrx	Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense Stockbasedcompensationexpenseassociatedwithsellinggeneralandadministrativeexpense	5370000	USD
CY2020Q3	lxrx	Sellinggeneralandadministrativeexpenses Sellinggeneralandadministrativeexpenses	11997000	USD
CY2019Q3	lxrx	Sellinggeneralandadministrativeexpenses Sellinggeneralandadministrativeexpenses	13898000	USD
	lxrx	Sellinggeneralandadministrativeexpenses Sellinggeneralandadministrativeexpenses	40798000	USD
	lxrx	Sellinggeneralandadministrativeexpenses Sellinggeneralandadministrativeexpenses	42271000	USD
CY2020Q3	us-gaap	Impairment Of Real Estate ImpairmentOfRealEstate	0	USD
CY2019Q3	us-gaap	Impairment Of Real Estate ImpairmentOfRealEstate	0	USD
CY2020Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1600000	USD
	us-gaap	Impairment Of Real Estate ImpairmentOfRealEstate	0	USD
CY2020Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2019Q3	us-gaap	Asset Impairment Charges AssetImpairmentCharges	28638000	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	28638000	USD
CY2020Q3	us-gaap	Operating Expenses OperatingExpenses	52777000	USD
CY2019Q3	us-gaap	Operating Expenses OperatingExpenses	69772000	USD
	us-gaap	Operating Expenses OperatingExpenses	196956000	USD
	us-gaap	Operating Expenses OperatingExpenses	124684000	USD
CY2020Q3	lxrx	Gain On Sale Of Non Financial Assets GainOnSaleOfNonFinancialAssets	132818000	USD
CY2019Q3	lxrx	Gain On Sale Of Non Financial Assets GainOnSaleOfNonFinancialAssets	0	USD
	lxrx	Gain On Sale Of Non Financial Assets GainOnSaleOfNonFinancialAssets	132818000	USD
	lxrx	Gain On Sale Of Non Financial Assets GainOnSaleOfNonFinancialAssets	0	USD
CY2020Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	86675000	USD
CY2019Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	224676000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-40342000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	188662000	USD
CY2020Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-255000	USD
CY2019Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-255000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
CY2020Q3	us-gaap	Interest Expense InterestExpense	4118000	USD
CY2019Q3	us-gaap	Interest Expense InterestExpense	5204000	USD
	us-gaap	Interest Expense InterestExpense	14374000	USD
	us-gaap	Interest Expense InterestExpense	15485000	USD
CY2020Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	301000	USD
CY2019Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	600000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1892000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	2080000	USD
CY2020Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	82603000	USD
CY2019Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	220072000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-53079000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	175257000	USD
CY2020Q3	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
CY2019Q3	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-6014000	USD
	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0	USD
	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-6014000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	82603000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	226086000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-53079000	USD
	us-gaap	Net Income Loss NetIncomeLoss	181271000	USD
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.77
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.50
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.71
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.71
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.95
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.50
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.59
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	107309000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106272000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106974000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106200000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	117552000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	116640000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	106974000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	116742000	shares
CY2020Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-277000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-50000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-49000	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	48000	USD
CY2020Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	82326000	USD
CY2019Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	226036000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-53128000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	181319000	USD
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-26405000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3411000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	USD
CY2019Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	941000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	45000	USD
CY2019Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-45687000	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3766000	USD
CY2019Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	53000	USD
CY2019Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-64886000	USD
CY2019Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3562000	USD
CY2019Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-50000	USD
CY2019Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	164712000	USD
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	117101000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4432000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	2000	USD
CY2020Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	923000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-66611000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	776000	USD
CY2020Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	54777000	USD
CY2020Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4258000	USD
CY2020Q2	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	187000	shares
CY2020Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	0	USD
CY2020Q2	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	103000	USD
CY2020Q2	us-gaap	Net Income Loss NetIncomeLoss	-69071000	USD
CY2020Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-548000	USD
CY2020Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-10687000	USD
CY2020Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1904000	USD
CY2020Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	9333000	shares
CY2020Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	14096000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	82603000	USD
CY2020Q3	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-277000	USD
CY2020Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	87639000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-53079000	USD
	us-gaap	Net Income Loss NetIncomeLoss	181271000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2590000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2719000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	10594000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	10739000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	995000	USD
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1087000	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-6014000	USD
	lxrx	Gain On Sale Of Non Financial Assets GainOnSaleOfNonFinancialAssets	132818000	USD
	lxrx	Gain On Sale Of Non Financial Assets GainOnSaleOfNonFinancialAssets	0	USD
	us-gaap	Impairment Of Real Estate ImpairmentOfRealEstate	1600000	USD
	us-gaap	Impairment Of Real Estate ImpairmentOfRealEstate	0	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
	us-gaap	Asset Impairment Charges AssetImpairmentCharges	28638000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-255000	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-52201000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	50917000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-345000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-204000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	6008000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	3305000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-314000	USD
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-330000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	14281000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-645000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-25929000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-108730000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	138178000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	33000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	70000	USD
CY2020Q3	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	160385000	USD
	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	53197000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	176987000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	229500000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	130600000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	336655000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-46457000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1026000	USD
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	941000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	210760000	USD
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	963000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-211786000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1904000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	16139000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	89817000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	36112000	USD
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	80386000	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52251000	USD
CY2019Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	170203000	USD
	us-gaap	Interest Paid Net InterestPaidNet	16892000	USD
	us-gaap	Interest Paid Net InterestPaidNet	13243000	USD
CY2020Q3	lxrx	Liabilities Assumed By Ter Sera LiabilitiesAssumedByTerSera	3180000	USD
CY2020Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	14096000	USD
	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the period. Actual results could differ from those estimates.</span>
CY2019Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	3200000	USD
CY2019Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	200000	USD
CY2019Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	900000	USD
CY2017Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	24700000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	19700000	USD
CY2020Q3	us-gaap	Intangible Assets Net Including Goodwill IntangibleAssetsNetIncludingGoodwill	18500000	USD
CY2020Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	0	USD
CY2020Q3	lxrx	Accrued Research And Development Services Current AccruedResearchAndDevelopmentServicesCurrent	50217000	USD
CY2019Q4	lxrx	Accrued Research And Development Services Current AccruedResearchAndDevelopmentServicesCurrent	29033000	USD
CY2020Q3	lxrx	Accrued Compensation And Benefits Current AccruedCompensationAndBenefitsCurrent	6023000	USD
CY2019Q4	lxrx	Accrued Compensation And Benefits Current AccruedCompensationAndBenefitsCurrent	9644000	USD
CY2020Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	553000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	553000	USD
CY2020Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1704000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2921000	USD
CY2020Q3	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	58497000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	42151000	USD
CY2020Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	300000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1200000	USD
CY2019Q3	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	400000	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1300000	USD
CY2020Q3	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	160400000	USD
CY2020Q3	lxrx	Gain On Sale Of Non Financial Assets GainOnSaleOfNonFinancialAssets	132800000	USD
	lxrx	Ter Sera Maximum Development Regulatory And Commercial Milestones TerSeraMaximumDevelopmentRegulatoryAndCommercialMilestones	65000000	USD
CY2020Q3	lxrx	Xermelo Pretax Net Loss XermeloPretaxNetLoss	-2100000	USD
	lxrx	Xermelo Pretax Net Loss XermeloPretaxNetLoss	-12100000	USD
CY2019Q3	lxrx	Xermelo Pretax Net Loss XermeloPretaxNetLoss	-4100000	USD
	lxrx	Xermelo Pretax Net Loss XermeloPretaxNetLoss	-10800000	USD
	us-gaap	Severance Costs1 SeveranceCosts1	5500000	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
	us-gaap	Realized Investment Gains Losses RealizedInvestmentGainsLosses	0	USD
CY2020Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	52251000	USD
CY2020Q3	us-gaap	Available For Sale Securities AvailableForSaleSecurities	59195000	USD
CY2020Q3	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	111446000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	36112000	USD
CY2019Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	235547000	USD
CY2019Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	271659000	USD
CY2014Q4	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	87500000	USD
CY2014Q4	lxrx	Conv Debt Instrument Interest Rate Stated Percentage ConvDebtInstrumentInterestRateStatedPercentage	0.0525
CY2020Q3	lxrx	Convertible Debt Exchange Total Principal Amount ConvertibleDebtExchangeTotalPrincipalAmount	75800000	USD
CY2020Q3	lxrx	Convertible Debt Exchange September Share Payment ConvertibleDebtExchangeSeptemberSharePayment	9332471	shares
CY2020Q3	lxrx	Convertible Debt Exchange September Cash Portion ConvertibleDebtExchangeSeptemberCashPortion	44000000.0	USD
CY2020Q3	lxrx	Accrued Interest On Convertible AccruedInterestOnConvertible	1100000	USD
CY2020Q3	lxrx	Convertible Debt Exchange September Principal Amount ConvertibleDebtExchangeSeptemberPrincipalAmount	-67100000	USD
CY2020Q3	lxrx	Convertible Debt Exchange ConvertibleDebtExchange	8400000	USD
CY2020Q3	lxrx	Convertible Debt Exchange Remaining Notes ConvertibleDebtExchangeRemainingNotes	20000000.0	USD
CY2014Q4	lxrx	Conv Debt Instrument Interest Rate Stated Percentage ConvDebtInstrumentInterestRateStatedPercentage	0.0525
CY2014Q4	us-gaap	Debt Instrument Convertible Conversion Ratio1 DebtInstrumentConvertibleConversionRatio1	118.4553
CY2014Q4	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	8.442
CY2014Q4	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	3400000	USD
CY2020Q3	us-gaap	Unamortized Debt Issuance Expense UnamortizedDebtIssuanceExpense	130000	USD
CY2020Q3	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	15400000	USD
CY2018Q3	lxrx	Mortgage Debt Instrument Revere Lxrx MortgageDebtInstrument_Revere_LXRX	12900000	USD
CY2018Q3	lxrx	Mortgage Debt Interest Rate Base Revere Lxrx MortgageDebtInterestRate_Base_Revere_LXRX	0.055
CY2018Q3	lxrx	Mortgage Debt Interest Rate Base Plus Revere Lxrx MortgageDebtInterestRateBasePlus_Revere_LXRX	0.075
CY2018Q3	lxrx	Mortgage Debt Balloon Payment Lxrx MortgageDebtBalloonPayment_LXRX	10300000	USD
CY2020Q3	lxrx	Mortgage Debt Instrument Revere Lxrx MortgageDebtInstrument_Revere_LXRX	11000000.0	USD
CY2017Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	150000000.0	USD
CY2020Q3	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.09
CY2017Q4	us-gaap	Deferred Finance Costs Gross DeferredFinanceCostsGross	4100000	USD
	lxrx	Lxrx Sanofiterminationcashpayment Lxrx_Sanofiterminationcashpayment	26000000	USD
	lxrx	Lxrx Sanofiterminationcashpayment Lxrx_Sanofiterminationcashpayment	26000000	USD
CY2020Q3	lxrx	Ipsen Total Payments IpsenTotalPayments	47200000	USD
CY2015Q1	lxrx	Ipsen Total Upfront Payments IpsenTotalUpfrontPayments	24500000	USD
CY2017Q1	lxrx	Ipsen Milestone Payment IpsenMilestonePayment	6400000	USD
CY2018Q1	lxrx	Ipsen Milestone Payment Received IpsenMilestonePaymentReceived	5100000	USD
CY2017Q4	lxrx	Ipsen Milestone Payment Received IpsenMilestonePaymentReceived	3800000	USD
CY2017Q4	lxrx	Ipsen Milestone Payment Received IpsenMilestonePaymentReceived	3800000	USD
CY2019Q4	lxrx	Ipsen Milestone Payment Received IpsenMilestonePaymentReceived	1300000	USD
CY2019Q1	lxrx	Ipsen Milestone Payment Received IpsenMilestonePaymentReceived	2300000	USD
	lxrx	Ipsen Maximum Regulatory And Commercial Milestones IpsenMaximumRegulatoryAndCommercialMilestones	9600000	USD
CY2014Q4	lxrx	Ipsen Maximum Sales Milestones IpsenMaximumSalesMilestones	72000000	EUR
CY2015Q1	lxrx	Ipsen Total Upfront Payments IpsenTotalUpfrontPayments	24500000	USD
CY2015Q1	lxrx	Ipsen Total Upfront Payments IpsenTotalUpfrontPayments	24500000	USD
CY2015	lxrx	Ipsen Revenue Allocatedto License Deliverable IpsenRevenueAllocatedtoLicenseDeliverable	21200000	USD
CY2015Q1	lxrx	Ipsen Total Upfront Payments IpsenTotalUpfrontPayments	24500000	USD
CY2016	lxrx	Ipsen Revenue Allocatedto License Deliverable IpsenRevenueAllocatedtoLicenseDeliverable	1400000	USD
CY2014Q4	lxrx	Ipsen Revenue Allocatedto Development Deliverable IpsenRevenueAllocatedtoDevelopmentDeliverable	1700000	USD
CY2014Q4	lxrx	Ipsen Revenue Allocatedto Committee Deliverable IpsenRevenueAllocatedtoCommitteeDeliverable	100000	USD
	lxrx	Ipsen Revenue Recognized IpsenRevenueRecognized	300000	USD
	lxrx	Ipsen Revenue Recognized IpsenRevenueRecognized	3500000	USD
	lxrx	Ipsen Royalty Income Lxrx IpsenRoyaltyIncome_LXRX	300000	USD
	lxrx	Lxrx Sanofiterminationcashpayment Lxrx_Sanofiterminationcashpayment	208000000	USD
CY2020Q3	lxrx	Lxrx Sanofiterminationcashpayment Lxrx_Sanofiterminationcashpayment	208000000	USD
	lxrx	Lxrx Sanofi Initial Cash Payment Lxrx_sanofiInitialCashPayment	26000000	USD
CY2020Q3	lxrx	Lxrx Sanofi Initial Cash Payment Lxrx_sanofiInitialCashPayment	26000000	USD
	lxrx	Sanofi Revenue Recognized SanofiRevenueRecognized	286000000.0	USD
	lxrx	Sanofi Revenue Recognized SanofiRevenueRecognized	286000000.0	USD
CY2020Q3	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	1258000	USD
CY2020Q3	lxrx	Asset Sale Price AssetSalePrice	11900000	USD
CY2020Q2	us-gaap	Asset Impairment Charges AssetImpairmentCharges	1600000	USD
CY2020Q3	us-gaap	Net Income Loss NetIncomeLoss	82603000	USD
CY2019Q3	us-gaap	Net Income Loss NetIncomeLoss	226086000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-53079000	USD
	us-gaap	Net Income Loss NetIncomeLoss	181271000	USD
CY2019Q3	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	1277000	USD
	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	0	USD
	us-gaap	Dilutive Securities Effect On Basic Earnings Per Share Other DilutiveSecuritiesEffectOnBasicEarningsPerShareOther	3790000	USD
CY2020Q3	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Diluted UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted	83861000	USD
CY2019Q3	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Diluted UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted	227363000	USD
	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Diluted UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted	-53079000	USD
	us-gaap	Undistributed Earnings Loss Allocated To Participating Securities Diluted UndistributedEarningsLossAllocatedToParticipatingSecuritiesDiluted	185061000	USD
CY2020Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	107309000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106272000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106974000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	106200000	shares
CY2020Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	51000	shares
CY2019Q3	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	3000	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	177000	shares
CY2020Q3	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	10192000	shares
CY2019Q3	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	10365000	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	0	shares
	us-gaap	Incremental Common Shares Attributable To Conversion Of Debt Securities IncrementalCommonSharesAttributableToConversionOfDebtSecurities	10365000	shares
CY2020Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	117552000	shares
CY2019Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	116640000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	106974000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	116742000	shares
CY2020Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.77
CY2019Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.13
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.50
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.71
CY2020Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.71
CY2019Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.95
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.50
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.59
CY2020Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11773000	shares
CY2019Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10576000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11859000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8452000	shares

Files In Submission

Name	View Source	Status
0001062822-20-000067-index-headers.html	Edgar Link	pending
0001062822-20-000067-index.html	Edgar Link	pending
0001062822-20-000067.txt	Edgar Link	pending
0001062822-20-000067-xbrl.zip	Edgar Link	pending
exh11openmarketsaleagr.htm	Edgar Link	pending
exh311certificationofp.htm	Edgar Link	pending
exh312certificationofp.htm	Edgar Link	pending
exh321certificationofp.htm	Edgar Link	pending
exh51veopinion10-30x20.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
lxrx-20200930.htm	Edgar Link	pending
lxrx-20200930.xsd	Edgar Link	pending
lxrx-20200930_cal.xml	Edgar Link	unprocessable
lxrx-20200930_def.xml	Edgar Link	unprocessable
lxrx-20200930_htm.xml	Edgar Link	completed
lxrx-20200930_lab.xml	Edgar Link	unprocessable
lxrx-20200930_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2020 Q4 Form 10-Q Financial Statement

#000106282220000067 Filed on October 30, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX LEXICON PHARMACEUTICALS, INC. Stock $lxrx

2020 Q4 Form 10-Q Financial Statement

#000106282220000067 Filed on October 30, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$LXRX
LEXICON PHARMACEUTICALS, INC. Stock $lxrx